Literature DB >> 23102883

Prognostic utility of BCIS myocardial jeopardy score for classification of coronary disease burden and completeness of revascularization.

Kalpa De Silva1, Geraint Morton, Pierre Sicard, Eric Chong, Andreas Indermuehle, Brian Clapp, Martyn Thomas, Simon Redwood, Divaka Perera.   

Abstract

Several coronary disease scoring systems have been developed to predict procedural risk during revascularization. Many vary in complexity, do not specifically account for myocardium at risk, and are not applicable across all patient subsets. The British Cardiovascular Intervention Society myocardial jeopardy score (BCIS-JS) addresses these limitations and is applicable to all patients, including those with coronary artery bypass grafts or left main stem disease. We assessed the prognostic relevance of the BCIS-JS in patients undergoing percutaneous coronary intervention (PCI). A total of 663 patients who underwent PCI with previous left ventricular function assessment were retrospectively assessed for inclusion, incorporating 221 with previous coronary artery bypass grafting. Blinded observers calculated the BCIS-JS, before (BCIS-JS(PRE)) and after (BCIS-JS(POST)) PCI, using the revascularization index (RI) (RI = [BCIS-JS(PRE) - BCIS-JS(POST)]/BCIS-JS(PRE)), quantifying the extent of revascularization, 1 indicating full revascularization and 0 indicating no revascularization. The primary end point all-cause mortality, tracked via the Office of National Statistics. A total of 660 patients were included (66 ± 10.7 years), with 43 deaths (6.5%) occurring during 2.6 ± 1.1 years after PCI. All-cause mortality was directly related to BCIS-JS(PRE) (hazard ratio [HR] 2.96, 95% confidence interval [CI] 1.71 to 5.15, p = 0.001) and BCIS-JS(POST) (HR 4.02, 95% CI 2.41 to 6.68, p = 0.001). A RI of <0.67 was associated with increased mortality compared to a RI of ≥0.67 (HR 4.13, 95% CI 1.91 to 8.91, p = 0.0001). On multivariate analysis, a RI <0.67 (HR 1.99, 95% CI 1.03 to 3.87, p = 0.04), left ventricular dysfunction (HR 2.03, 95% CI 1.25 to 3.30, p = 0.004) and renal impairment (HR 3.75, 95% CI 1.48 to 8.64, p = 0.005) were independent predictors of mortality. In conclusion, the BCIS-JS predicts mortality after PCI and can assess the degree of revascularization, with more complete revascularization conferring a survival advantage in the medium term.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23102883     DOI: 10.1016/j.amjcard.2012.09.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  The assessment of ischaemic burden: validation of a functional jeopardy score against cardiovascular magnetic resonance perfusion imaging.

Authors:  Shazia T Hussain; Geraint Morton; Kalpa De Silva; Roy Jogiya; Andreas Schuster; Matthias Paul; Divaka Perera; Eike Nagel
Journal:  Clin Res Cardiol       Date:  2016-10-20       Impact factor: 5.460

2.  Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry.

Authors:  Francesco Burzotta; Giulio Russo; Flavio Ribichini; Anna Piccoli; Domenico D'Amario; Lazzaro Paraggio; Leonardo Previ; Gabriele Pesarini; Italo Porto; Antonio Maria Leone; Giampaolo Niccoli; Cristina Aurigemma; Diana Verdirosi; Filippo Crea; Carlo Trani
Journal:  J Interv Cardiol       Date:  2019-04-09       Impact factor: 2.279

3.  Intra-aortic Balloon Counterpulsation for High-Risk Percutaneous Coronary Intervention: Defining Coronary Responders.

Authors:  Natalia Briceno; Kalpa De Silva; Matthew Ryan; Tiffany Patterson; Kevin O'Gallagher; Howard Ellis; Simone Rivolo; Jack Lee; Simon Redwood; Ajay M Shah; Michael Marber; Divaka Perera
Journal:  J Cardiovasc Transl Res       Date:  2019-03-15       Impact factor: 4.132

4.  Can we have a rationalized selection of intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation in the catheterization laboratory?

Authors:  Giulio Russo; Francesco Burzotta; Cristina Aurigemma; Daniela Pedicino; Enrico Romagnoli; Carlo Trani
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.